Z
Zvonko Milicevic
Researcher at Eli Lilly and Company
Publications - 79
Citations - 3050
Zvonko Milicevic is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Dulaglutide & Diabetes mellitus. The author has an hindex of 22, co-authored 64 publications receiving 2346 citations. Previous affiliations of Zvonko Milicevic include University of Zagreb.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan P. Frias,Michael A. Nauck,Joanna Van,Mark E Kutner,Xuewei Cui,Charles Benson,Shweta Urva,Ruth E. Gimeno,Zvonko Milicevic,Deborah A. Robins,Axel Haupt +10 more
TL;DR: The effect of LY3298176 on change in HbA1c was dose-dependent and did not plateau, and the modified intention-to-treat and safety populations included 316 participants.
Journal ArticleDOI
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.
Itamar Raz,Peter W.F. Wilson,Krzysztof Strojek,Irina Kowalska,Velimir Bozikov,Anselm K. Gitt,György Jermendy,Barbara N. Campaigne,Lisa Kerr,Zvonko Milicevic,Scott J. Jacober +10 more
TL;DR: Treating diabetic survivors of AMI with prandial versus basal strategies achieved differences in fastingBlood glucose, less-than-expected differences in postprandial blood glucose, similar levels of A1C, and no difference in risk for future cardiovascular event rates.
Journal ArticleDOI
Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
Michael A. Nauck,Ruth S. Weinstock,Guillermo E. Umpierrez,Bruno Guerci,Zachary Skrivanek,Zvonko Milicevic +5 more
TL;DR: Both dulaglutide doses demonstrated superior glycemic control versus sitagliptin at 52 weeks with an acceptable tolerability and safety profile.
Journal ArticleDOI
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
Lawrence Blonde,Johan Jendle,Jorge Luiz Gross,Vincent Woo,Honghua Jiang,Jessie L. Fahrbach,Zvonko Milicevic +6 more
TL;DR: Dulaglutide in combination with lispro resulted in a significantly greater improvement in glycaemic control than did glargine and represents a new treatment option for patients unable to achieve targets with conventional insulin.
Journal ArticleDOI
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Bernhard Ludvik,Juan P. Frias,Francisco J. Tinahones,Julio Wainstein,Honghua Jiang,Kenneth E. Robertson,Luis-Emilio Garcia-Perez,D. Bradley Woodward,Zvonko Milicevic +8 more
TL;DR: The safety and efficacy of the addition of the once-weekly GLP-1 receptor agonist dulaglutide to the ongoing treatment regimen in patients whose diabetes is inadequately controlled with SGLT2 inhibitors, with or without metformin is assessed.